ArticleBiomarkers in medicine2025
Predictive value of 18F-FDG PET/CT metabolic parameters for lymph node metastasis of non-small cell lung cancer.
Article in Biomarkers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Development of PET/CT-clinical nomograms for predicting lymph node metastasis in primary lung cancer.European radiology · 2026Article
- Integrated primary tumor and all metastatic lymph nodes radiomics from 18 F-FDG PET/CT for precise M1 subclassification in nasopharyngeal carcinoma.BMC cancer · 2026Article
- Prediction of lymph node metastasis in non-small cell lung cancer and its correlation with Ki-67 expression: a comparative study between intravoxel incoherent motion imaging andBMC medical imaging · 2026Article
- Deep learning-radiomics-SUVmax integration fromFrontiers in oncology · 2026Article
- Development of a predictive model for lymph node metastasis in esophageal cancer usingJournal of gastrointestinal oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLymph node metastasis is closely associated with the prognosis of patients with non-small cell lung cancer (NSCLC). This study aimed to evaluate the role of preoperative 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) parameters in mediastinal lymph node metastasis in NSCLC.
methodsOne hundred patients with NSCLC who underwent surgery, systematic lymph node dissection, who had undergone 18FFDG PET/CT for initial staging were divided into two groups: lymph node metastasis and non-metastasis. The maximum standardized uptake value (SUVmax), average standardized uptake value (SUVmean), SUV in the liver (SURliver), mediastinal blood pool (SURblood), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were detected in both groups. Receiver operating characteristic (ROC) curves were used to evaluate the parameters for predicting the diagnostic efficacy.
resultsThe SUVmax, SUVmean, SURblood, SURliver, MTV, and TLG were higher in the group with lymph node metastasis than in the group without lymph node metastasis. The ROC analysis showed that 18F-FDG PET/CT demonstrated acceptable predictive ability with AUC of 0.964 (95% CI, 0.930-0.998).
conclusionsThe relative 18F-FDG PET/CT primary uptake and substitution parameters showed acceptable predictive efficacy for mediastinal lymph node metastasis in patients with NSCLC. Additional, SURblood has potential for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.